- Home
- PACK vs ALT Comparison
PACK vs ALT Comparison
Compare PACK & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PACK
- ALT
- Stock Information
- Founded
- PACK 1972
- ALT 1997
- Country
- PACK United States
- ALT United States
- Employees
- PACK N/A
- ALT N/A
- Industry
- PACK Containers/Packaging
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- PACK Consumer Discretionary
- ALT Health Care
- Exchange
- PACK Nasdaq
- ALT Nasdaq
- Market Cap
- PACK 653.6M
- ALT 529.9M
- IPO Year
- PACK N/A
- ALT N/A
- Fundamental
- Price
- PACK $6.47
- ALT $6.83
- Analyst Decision
- PACK Buy
- ALT Strong Buy
- Analyst Count
- PACK 3
- ALT 8
- Target Price
- PACK $9.50
- ALT $19.71
- AVG Volume (30 Days)
- PACK 180.6K
- ALT 2.5M
- Earning Date
- PACK 03-10-2025
- ALT 11-12-2024
- Dividend Yield
- PACK N/A
- ALT N/A
- EPS Growth
- PACK N/A
- ALT N/A
- EPS
- PACK N/A
- ALT N/A
- Revenue
- PACK $354,300,000.00
- ALT $52,000.00
- Revenue This Year
- PACK $10.49
- ALT N/A
- Revenue Next Year
- PACK $9.39
- ALT N/A
- P/E Ratio
- PACK N/A
- ALT N/A
- Revenue Growth
- PACK 8.91
- ALT N/A
- 52 Week Low
- PACK $3.85
- ALT $5.28
- 52 Week High
- PACK $9.04
- ALT $14.84
- Technical
- Relative Strength Index (RSI)
- PACK 39.65
- ALT 41.57
- Support Level
- PACK $6.22
- ALT $6.19
- Resistance Level
- PACK $6.44
- ALT $7.83
- Average True Range (ATR)
- PACK 0.22
- ALT 0.39
- MACD
- PACK -0.03
- ALT -0.04
- Stochastic Oscillator
- PACK 41.67
- ALT 39.02
About PACK Ranpak Holdings Corp
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. Geographically, it derives a majority of revenue from Europe/Asia. They generate revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and our network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.